by admin | May 4, 2024 | Article
March 10, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Manitoba effective April 1, 2024. For more information, please visit https://www.gov.mb.ca/health/mdbif/docs/bulletins/bulletin131.pdf
by admin | May 4, 2024 | Article
March 6, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Nova Scotia effective March 1, 2024. The public notice and listing criteria will appear on the Nova Scotia Pharmacare Programs website when the March Bulletin is...
by admin | May 4, 2024 | Article
February 15, 2024 – Lupus Canada is honoured to be a member of the CIAN group. Together our goal is to protect more Canadians to improve the quality of life and significantly reduce hospitalization for vulnerable people. On page 60 of the Heal Canada Digital...
by admin | Apr 19, 2024 | Article
January 24, 2024 – “As the world continues its return to pre-pandemic norms, many immunocompromised Canadians are still struggling to feel safe. Why aren’t we doing more for those left behind?” Please visit Left Behind: Immunocompromised Canadians Living in...
by admin | Apr 19, 2024 | Article
February 14, 2024 – “In the spring of 2022, even as COVID-19 restrictions were being lifted across the country (and the world), there was still a great deal of concern from immunocompromised patients about how they navigate the ‘post-pandemic world’. In response...
